Pre-clinical cardiovascular disease and surrogate endpoints in hypertension: Does race influence target organ damage independent of blood pressure?

Ethnicity and Disease

Volumn 8, Issue 2, 1998, Pages 138-148

  Devereux, Richard B ^a   Okin, Peter M ^a   Roman, Mary J ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Echocardiography; Electrocardiography; Hypertension; Hypertrophy

Indexed keywords

ARTERIOSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CAUCASIAN; ECHOCARDIOGRAPHY; ECHOGRAPHY; ELECTROCARDIOGRAPHY; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; NEGRO; PROGNOSIS; REVIEW; RISK; RISK FACTOR;

AFRICAN CONTINENTAL ANCESTRY GROUP; ARTERIOSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; ODDS RATIO; PROGNOSIS; RISK FACTORS;

EID: 0031604413     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
2. Bikkina M, Levy D, Evans JC, et al. Left ventricular mass and the risk of stroke in an elderly cohort. The Framingham Heart Study. JAMA. 1994; 272:33-36.
3. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345-352.
4. Mensah GA, Pappas TW, Koren MJ, Ulin RJ, Laragh JH, Devereux RB. Comparison of classification of hypertension severity by blood pressure level and World Health Organization criteria for prediction of concurrent cardiac abnormalities and subsequent complications in essential hypertension. J Hypertens. 1993;11:1433-1444.
5. Bolognese L, Dellavese P, Rossi L, Sarasso G, Bongo AS, Scianaro MC. Prognostic value of left ventricular mass in uncomplicated acute myocardial infarction and one-vessel coronary artery disease. Am J Cardiol. 1994;73:1-5.
6. Liao Y, Cooper RS, McGee DL, Mensah GA, Ghali JK. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA. 1995;273:1592-1597.
7. Liao Y, Cooper RS, Durazu-Arvizu R, Mensah GA, Ghali JK. Prediction of mortality risk by different methods of indexing for left ventricular mass. J Am Coll Cardiol. 1997;29:641-647.
8. Koren MJ, Ulin RJ, Laragh JH, Devereux RB. Reduction of left ventricular mass during treatment of essential hypertension is associated with improved prognosis. Am J Hypertens. 1991;4:1A.
9. Yurenev AP, Dyakonova HG, Novikov ID, Vitols A, Pahl L, Haynemann G, et al. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy. Multicenter trial. Am J Hypertens. 1992;5:182s-189s.
10. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994;90:1786-1793.
11. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens. 1995;13:1091-1105.
12. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobiggio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998;97:48-54.
13. Salonen JT, Salonen R. Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. Arterioscler Thromb. 1991;11: 1245-1249.
14. Kuller LH, Shemanski L, Psaty BM, Borhani NO, Gardin J, Haan MN, et al. Subclinical disease as an independent risk factor for cardiovascular disease. Circulation. 1995;92:720-726.
15. Salonen JT, Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation. 1993;87(suppl II):II-56-II-65.
16. Salonen JT, Salonen R. Arterial wall thickness, carotid atherosclerosis and the risk of myocardial infarction and cerebrovascular stroke. In: Touboul P-J, Crouse JR III, eds. Intima-Media Thickness: Predicting the Risk? New York, NY: Parthenon Publishing Group; 1996:97-104.
17. Belcaro G, Nicolaides AN, Laurora G, Cesarone MR, De Sanctis M, Incandela L, et al. Ultrasound morphology classification of the arterial wall and cardiovascular events in a 6-year follow-up study. Arterioscler Thromb Vase Biol. 1996;16:851-856.
18. Hodis HN, Mack WJ, LaBree L, Chao-ran L, Selzer RH. Progression of carotid intima-media thickness and coronary artery disease comparably predict clinical coronary events. Circulation. 1996 (suppl I); 94:1-122.
19. Dunn FG, Oigman W, Sungaard-Riise K, Messerli FH, Ventura H, Reisen E, et al. Racial differences in cardiac adaptation to essential hypertension determined by echocardiographic indexes. J Am Coll Cardiol. 1983;1:1348-1351.
20. Hammond IW, Alderman MH, Devereux RB, Lutas EM, Laragh JH. Contrast in cardiac anatomy and function between black and white patients with hypertension. J Natl Med Assoc. 1984;76: 247-255.
21. Hammond IW, Devereux RB, Alderman MH, Lutas EM, Spitzer MC, Crowley JS, et al. The prevalence and correlates of echocardiographic left ventricular hypertrophy among employed patients with uncomplicated hypertension. J Am Coll Cardiol. 1986;7:639-650.
22. Koren MJ, Mensah GA, Blake J, Laragh JH, Devereux RB. Comparison of left ventricular mass and geometry in black and white patients with essential hypertension. Am J Hypertension. 1993;6:815-823.
23. Liebson PR, Grandits G, Prineas R, Dianzumba S, Flack JM, Cutler JA, Grimm R, Stamler J. Echocardiographic correlates of left ventricular structure among 844 mildly hypertensive men and women in the Treatment of Mild Hypertension Study (TOMHS). Circulation. 1993:87:476-486.
24. Gottdiener JS, Reda DJ, Materson BJ, Massie BJ, Notargiacomo A, Hamburger RJ, et al. Importance of obesity, race and age to the cardiac and structural effects of hypertension. J Am Coll Cardiol. 1994;24:1492-1498.
25. Chutaverdi N, Athanassopoulos G, McKeigue PM, Marmot MG, Nihoyannopoulos P. Echocardiographic measures of left ventricular structure and their relation with rest and ambulatory blood pressure in blacks and whites in the United Kingdom. J Am Coll Cardiol. 1994;24:1499-1505.
26. Mayet J, Shahi M, Foale RA, Poulter NR, Sever PS, Thom SA. Racial differences in cardiac structure and function in essential hypertension. BMJ. 1994:308:1011-1014.
27. Abassade P, Lamour P, Lung B, Delbechi G, Guiomard A. L'hypertrophie ventriculaire gauche chez l'hypertendu. Une etude comparative entre des sujets Noirs africains et Blancs europeens. Ann Angeiol. 1996;45:567-572.
28. Bartel A, Heyden S, Tyroler HA, et al. Electrocardiographic predictors of coronary heart disease. Arch Intern Med. 1971;128:929-937.
29. Sutherland JE, Gazes PC, Keil JE, Gilbert GE, Knapp RG. Electrocardiographic abnormalities and 30-year mortality among white and black men of the Charleston Heart Study. Circulation. 1993; 88:2685-2692.
30. Lee DK, Marantz PR, Devereux RB, Kligfield P, Alderman MH. Left ventricular hypertrophy in black versus white hypertensives: standard electrocardiographic criteria overestimate racial differences in prevalence. JAMA. 1992;267:3294-3299.
31. Strogatz DS, Tyroler HA, Watkins LO, Hames CG. Electrocardiographic abnormalities and mortality among middle-aged black men and white men of Evans County, Georgia. J Chronic Dis. 1987;40:149-155.
32. Schmieder RE, Rockstroh JK, Luchters G, Hammerstein U, Messerli FH. Comparison of early target organ damage in blacks and whites with mild systemic arterial hypertension. Am J Cardiol. 1997;79:1695-1698.
33. Devereux RB, Agabiti-Rosei E, Dahlof B, Gosse P, Hahn RT, Okin PM, Roman MJ. Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials. J Hypertens. 1996;14 (suppl 2):s95-s102.
34. Breslin DJ, Gifford RW Jr, Fairbairn JF II. Essential hypertension: a twenty year follow-up study. Circulation. 1966;33:87-97.
35. Sokolow M, Perloff D. Prognosis of essential hypertension treated conservatively. Circulation. 1961;23:697-713.
36. Sullivan JM, Vander Zwaag R, El-Zecky F, Ramanathan KB, Mirvis DM. Left ventricular hypertrophy: effect on survival. J Am Coll Cardiol. 1993;22:508-513.
37. Kannel WB, Abbott RD. A prognostic comparison of asymptomatic left ventricular hypertrophy and unrecognized myocardial infarction. Am Heart J. 1986;111:391-397.
38. MacMahon S, Collins G, Rautaharju P, et al. for the Multiple Risk Factor Intervention Trial Research Group. Electrocardiographic left ventricular hypertrophy and effects of drug therapy in the Multiple Risk Factor Intervention Trial. Am J Cardiol. 1989; 63:202-210.
39. Isles CG, Walker LV, Beevers DG, et al. Mortality in the Glasgow blood pressure clinic. J Hypertens. 1987;4:141-156.
40. Casale PN, Devereux RB, Milner M, et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med. 1986;105:173-178.
41. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Left ventricular mass and incidence of coronary heart disease in an elderly cohort: The Framingham Study. Ann Intern Med. 1989;110: 101-108.
42. Quinones MA, Weiner DH, Shelton BJ, et al, for the SOLVD Investigators. Echocardiographic predictors of one-year clinical outcome in the Study of Left Ventricular Dysfunction (SOLVD) Trial and Registry: a study of 1,172 patients [abstract]. Circulation. 1993;90 (suppl I):I-304.
43. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int. 1989; 36:286-290.
44. Parfrey PS, Harnett JD, Griffiths SM, et al. The clinical course of left ventricular hypertrophy in dialysis patients. Nephron. 1990;55:114-120.
45. Aronow WS, Epstein S, Koenigsberg M, Schwartz KS. Usefulness of echocardiographic left ventricular hypertrophy, ventricular tachycardia and complex ventricular arrhythmias in predicting ventricular fibrillation or sudden death in elderly patients. Am J Cardiol. 1988;62:1124-1125.
46. Koren MJ, Savage DD, Casale PN, Laragh JH, Devereux RB. Changes in left ventricular mass predict risk in essential hypertension. Circulation. 1990;82(suppl III):III-29.
47. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450-458.
48. Yurenev AP, de Quattro V, Devereux RB. Hypertensive heart disease: relationship of silent ischemia to coronary artery disease and left ventricular hypertrophy. Am Heart J. 1990;120:928-933.
49. Gardin JM, Wagenknecht LE, Anton-Culver H, Flack J, Gidding S, Kurosaki T, et al. Relationship of cardiovascular risk factors to echocardiographic left ventricular mass in healthy young black and white adult men and women. The CARDIA study: Coronary Artery Risk Development in Young Adults. Circulation. 1995;92:380-387.
50. Fumo MT, Teeger S, Lang RM, Bednarz J, Sareli P, Murphy MB. Diurnal blood pressure variations and cardiac mass in American blacks and whites and South African blacks. Am J Hypertens. 1992; 5:111-116.
51. Howard G, Sharett AR, Heiss G, et al, for the ARIC Investigators. Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound. Stroke. 1993;24: 1297-1304.
52. Agostino RB Jr, Burke G, O'Leary D, Rewers M, Selby J, Savage PJ, et al. Ethnic differences in carotid wall thickness: The Insulin Resistance Atherosclerosis Study. Stroke. 1996;27:1744-1749.
53. Devereux RB, Dahlof B. Requirements for an informative trial of left ventricular hypertrophy regression. J Hum Hypertens. 1994;8:735-739.
54. Devereux RB, Dahlof B, Levy D, Pfeffer MA. Comparison of enalapril vs nifedipine to decrease left ventricular hypertrophy in systemic hypertension (The PRESERVE Trial). Am J Cardiol. 1996; 78:61-65.
55. Dahlof B, Devereux R, de Faire U, et al, for the LIFE Study Group. The Losartan Intervention for Endpoint Reduction (LIFE) Study in Hypertension. Rationale, design and methods. Am J Hypertens. 1997;10:705-713.
56. Bond G, et al. ELSA (European Lacidipine Study on Atherosclerosis). J Cardiovasc Pharmacol. 1994;23(suppl 5):s85-s87.
57. Devereux RB, Alderman MH. Role of preclinical cardiovascular disease in the evolution from risk factor exposure to clinical morbid event. Circulation. 1993;88:1444-1455.